PMID- 36221376
OWN - NLM
STAT- MEDLINE
DCOM- 20221013
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 101
IP  - 40
DP  - 2022 Oct 7
TI  - Prognostic significance of CD56 antigen in newly diagnosed multiple myeloma: A 
      real-world retrospective study.
PG  - e30988
LID - 10.1097/MD.0000000000030988 [doi]
LID - e30988
AB  - The prognostic value of plasma cell CD56 expression of patients with multiple 
      myeloma (MM) has been reported in many studies, but the results are 
      controversial. This study aimed to examine the prognostic significance of CD56 in 
      MM patients. Eighty seven patients with newly diagnosed MM were enrolled in this 
      study, and their clinical characteristics, immunophenotypes, and cytogenetics 
      were retrospectively analyzed to explore the prognostic significance of CD56 
      expression. Multiparameter flow cytometry was used to detect MM in bone marrow 
      samples from all patients. Patients were divided into 2 groups based on whether 
      they expressed CD56: CD56 + group and CD56 - group. After 4 cycles of 
      chemotherapy, the overall response rate of the CD56 - patients was lower than 
      that of the CD56 + patients (60.0% vs 81.1%, P = .036). Survival analysis showed 
      that the median progression-free survival (PFS) was 10 months for the CD56 - 
      group and 27 months for the CD56 + group (P = .007). The median overall survival 
      (OS) of patients for the CD56 - group was 25 months versus not reached in the 
      CD56 + group (P = .010). In addition, among the high-risk patients detected by 
      fluorescence in situ hybridization (FISH), the median PFS was 4 months for the 
      CD56 - group and 16 months for the CD56 + group (P = .012). The median OS of the 
      CD56 + group and CD56 - group was 36 months and 15 months, respectively, with 
      statistically significant differences (P = .017). Our study confirmed that CD56 - 
      patients with MM had a worse prognosis than that of CD56 + patients with MM. 
      Among the patients with >/= 2 high-risk cytogenetics, the existence of the CD56 
      negativity can further identify MM patients with poor PFS and OS.
CI  - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Li, Liping
AU  - Li L
AD  - Department of Oncology and Hematology, The Second Hospital of Jilin University, 
      Nanguan District, Changchun City, Jilin, China.
FAU - Li, Xiaofeng
AU  - Li X
FAU - Shang, An
AU  - Shang A
FAU - Zhao, Yan
AU  - Zhao Y
FAU - Jin, Lifang
AU  - Jin L
FAU - Zhao, Meng
AU  - Zhao M
FAU - Shen, Weizhang
AU  - Shen W
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (CD56 Antigen)
SB  - IM
MH  - CD56 Antigen
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Multiple Myeloma/genetics
MH  - Prognosis
MH  - Retrospective Studies
PMC - PMC9542762
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2022/10/13 06:00
MHDA- 2022/10/14 06:00
PMCR- 2022/10/07
CRDT- 2022/10/12 01:52
PHST- 2022/10/12 01:52 [entrez]
PHST- 2022/10/13 06:00 [pubmed]
PHST- 2022/10/14 06:00 [medline]
PHST- 2022/10/07 00:00 [pmc-release]
AID - 00005792-202210070-00053 [pii]
AID - 10.1097/MD.0000000000030988 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2022 Oct 7;101(40):e30988. doi: 
      10.1097/MD.0000000000030988.